SCHEMBL967441

SCHEMBL967441

CC(C)(C)c1ccc(OCCCO)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.56
CYP3A4 P08684 1/20 0.56
HRH3 Q9Y5N1 3/20 0.54
KDM4E B2RXH2 3/20 0.53
POLB P06746 3/20 0.50
KMT2A Q03164 3/20 0.50
MEN1 O00255 2/20 0.50
RAB9A P51151 3/20 0.49
MITF O75030 2/20 0.49
GAA P10253 1/20 0.49
ALDH1A1 P00352 1/20 0.48
APP P05067 1/20 0.47
XBP1 P17861 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
NPC1 O15118 2/20 0.46
CASP3 P42574 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
LMNA P02545 1/20 0.46
TP53 P04637 1/20 0.46
MAOB P27338 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9592076 0.94 SMN1; SMN2 (0.54) SMN1; SMN2CYP3A4HRH3KDM4EPOLB
SCHEMBL9590628 0.92 HRH3 (0.56) SMN1; SMN2CYP3A4HRH3KDM4EPOLB
SCHEMBL8956385 0.92 HRH3 (0.56) SMN1; SMN2CYP3A4HRH3KDM4EPOLB
SCHEMBL9590081 0.92 HRH3 (0.56) SMN1; SMN2CYP3A4HRH3KDM4EPOLB
SCHEMBL9593778 0.92 HRH3 (0.56) SMN1; SMN2CYP3A4HRH3KDM4EPOLB
SCHEMBL270793 0.90 SMN1; SMN2 (0.68) SMN1; SMN2CYP3A4HRH3KDM4EPOLB
SCHEMBL17912 0.88 KDM4E (0.56) SMN1; SMN2CYP3A4KDM4EPOLBKMT2A
SCHEMBL26120882 0.88 SMN1; SMN2 (0.53) SMN1; SMN2CYP3A4HRH3KDM4EPOLB
SCHEMBL20234326 0.87 HRH3 (0.61) SMN1; SMN2CYP3A4HRH3KDM4EPOLB
SCHEMBL22248702 0.87 HRH3 (0.62) SMN1; SMN2CYP3A4HRH3KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2259137-B1 METHOD FOR PRODUCING A OF LITHOGRAPHIC PRINTING PLATE FUJIFILM CORP (JP) 2016-08-31 EP disclosed
EP-2915796-A1 PROPYL-PHENYL-ETHER DERIVATIVE AND MELANOGENESIS INHIBITOR, SKIN-LIGHTENING AGENT, ANTIMICROBIAL AGENT, AND COSMETIC CONTAINING SAID PROPYL-PHENYL-ETHER DERIVATIVE Seiwa Kasei Company, Limited (JP) 2015-09-09 EP disclosed
US-20150238401-A1 PROPYL-PHENYL-ETHER DERIVATIVE, AND MELANOGENESIS INHIBITOR, SKIN-LIGHTENING AGENT, ANTIMICROBIAL AGENT AND COSMETIC CONTAINING SAID PROPYL-PHENYL-ETHER DERIVATIVE SEIWA KASEI COMPANY, LIMITED (JP) 2015-08-27 US disclosed
US-20150238401-A1 PROPYL-PHENYL-ETHER DERIVATIVE, AND MELANOGENESIS INHIBITOR, SKIN-LIGHTENING AGENT, ANTIMICROBIAL AGENT AND COSMETIC CONTAINING SAID PROPYL-PHENYL-ETHER DERIVATIVE SEIWA KASEI COMPANY, LIMITED (JP) 2015-08-27 US disclosed
WO-2014069555-A1 PROPYL-PHENYL-ETHER DERIVATIVE AND MELANOGENESIS INHIBITOR, SKIN-LIGHTENING AGENT, ANTIMICROBIAL AGENT, AND COSMETIC CONTAINING SAID PROPYL-PHENYL-ETHER DERIVATIVE 株式会社成和化成 (JP) 2014-05-08 WO disclosed
US-20110168044-A1 METHOD OF PREPARING LITHOGRAPHIC PRINTING PLATE FUJIFILM CORPORATION (JP) 2011-07-14 US disclosed
EP-2330464-A1 PROCESS FOR PRODUCING LITHOGRAPHIC PRINTING PLATE FUJIFILM Corporation (JP) 2011-06-08 EP disclosed
US-20110020751-A1 LITHOGRAPHIC PRINTING PLATE PRECURSOR AND PRODUCTION PROCESS OF LITHOGRAPHIC PRINTING PLATE USING THE PRECURSOR FUJIFILM CORPORATION (JP) 2011-01-27 US disclosed
EP-2259137-A1 ORIGINAL PLATE FOR LITHOGRAPHIC PRINTING PLATE, AND METHOD FOR PRODUCTION OF LITHOGRAPHIC PRINTING PLATE USING THE SAME FUJIFILM Corporation (JP) 2010-12-08 EP disclosed
US-7741289-B2 Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof SCHERING CORPORATION (US) 2010-06-22 US disclosed
US-20070155675-A1 Substituted azetidinone compunds, processes for preparing the same, formulations and uses thereof SCHERING CORPORATION (US) 2007-07-05 US disclosed
US-7235543-B2 Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof SCHERING CORPORATION (US) 2007-06-26 US disclosed
US-7196082-B2 Ophthalmic compositions for treating ocular hypertension MERCK & CO. INC. (US) 2007-03-27 US disclosed
US-5242936-A Phenoxy alkanol esters for treatment of allergic conditions Berger, Frank M. (US) 1993-09-07 US disclosed
US-5021460-A P-alkyl phenoxy alkanols for the treatment of allergic conditions Berger, Frank M. (US) 1991-06-04 US disclosed
US-4816491-A Treatment of allergic conditions using indanyloxy-alkanol derivatives Berger, Frank M. (US) 1989-03-28 US disclosed
EP-0162975-B1 P-ALKYL OR CYCLOALKYL PHENOXY ALKANOLS AND ALKANOL ESTERS AND USE FOR THE TREATMENT OF ALLERGIC CONDITIONS PHARMACO DEVELOPMENT PARTNERS (US) 1988-07-27 EP disclosed
EP-0162975-A1 P-alkyl or cycloalkyl phenoxy alkanols and alkanol esters and use for the treatment of allergic conditions PHARMACO DEVELOPMENT PARTNERS (US) 1985-12-04 EP disclosed
US-4543362-A P-Alkyl or cycloalkyl phenoxy alkanols and alkanol esters and process for the treatment of allergic conditions Berger, Frank M. (US) 1985-09-24 US disclosed
US-4451474-A T-Butyl-phenoxy-alkylene esters of benzoic and nicotinic acids, compositions containing same and their antihistaminic method of use Berger, Frank M. (US) 1984-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150238401-A1 PROPYL-PHENYL-ETHER DERIVATIVE, AND MELANOGENESIS INHIBITOR, SKIN-LIGHTENING AGENT, ANTIMICROBIAL AGENT AND COSMETIC CONTAINING SAID PROPYL-PHENYL-ETHER DERIVATIVE TYR, MITF, MC1R SMN1; SMN2 4407/4885CYP3A4 815/4885HRH3 3426/4885
US-20070155675-A1 Substituted azetidinone compunds, processes for preparing the same, formulations and uses thereof APOB, NPC1L1, CYP46A1 SMN1; SMN2 207/4885CYP3A4 594/4885HRH3 4710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.